Lapatinib, an orally active, small molecule, reversible inhibitor of EGFR and HER2, is being evaluated for treatment of cancers with EGFR expression and HER2 overexpression, including cancers that are refractory to standard therapy. This evidence concerns the gene ERBB2 and cancer.